|Application ||WB, IHC, IF, FC, IP|
|Reactivity||Human, Mouse, Rat|
|Other Names||Rab9 effector protein with kelch motifs, 40 kDa Rab9 effector protein, p40, RABEPK, RAB9P40|
|Target/Specificity||A synthetic peptide (ENNAQTQFSEPQY) corresponding to aa5-17 of human p40|
|Application Note||Flow Cytometry : 0.5-1ug/million cells|
Immunofluorescence : 1-2ug/ml
Western Blotting : 0.5-1.0 µg/ml
Immunoprecipitation : 1-2ug/500ug protein lysate
Immunohistology (formalin-fixed) : 1-2ug/ml for 30 minutes at RT
(Staining of formalin-fixed tissues requires boiling tissue sections in 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 minutes).
|Format||0.5 ml at 200ug/ml with BSA and azide|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||p63 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Rab9 effector required for endosome to trans-Golgi network (TGN) transport.|
|Cellular Location||Cytoplasm. Endosome membrane. Note=Interaction with PIP5K3 and subsequent phosphorylation recruits it to the endosomal membrane|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
p40 (p63 delta) is a marker recently determined to be highly specific for squamous basal cells in the immunohistochemistry (IHC) application. The current more routinely recommended marker, p63, appears to have less specificity compared to p40, especially on squamous cell tumors. The ability to differentiate between lung adenocarcinoma vs. squamous cell carcinoma is difficult and has bearing on the different therapeutic avenues for each subtype treatment. p63 antibody’s ability to distinguish between the tumor types appears to be inferior when compared to p40. The ability to utilize an antibody probe for p40 as a squamous cell marker bolsters its use for future sub-classification of lung cancers, especially by immunohistochemical techniques.
1. Bishop, JA et. al. Modern Pathology 25 : 405–415
2. Scagliotti G et. al. J Thorac Oncol 6:64–70.
3. Kargi A et. al. Appl Immunohistochem Mol Morphol 15:415–420.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.